Диссертация (1139842), страница 19
Текст из файла (страница 19)
21. – №. 7. – С. 521-532.67. Besarab A., Hörl W. H., Silverberg D. Iron metabolism, iron deficiency,thrombocytosis, and the cardiorenal anemia syndrome // The Oncologist. –2009. – Т. 14. – №1. – С. 22-33.68. Blum A., Miller H. Role of cytokines in heart failure // American heartjournal. – 1998. – Т. 135. – №. 2.
– С. 181-186.69. Böhm M., Robertson, M., Ford, I. et al. Influence of cardiovascular andnoncardiovascular co-morbidities on outcomes and treatment effect of heartrate reduction with ivabradine in stable heart failure (from the SHIFT Trial)//American Journal of Cardiology. – 2015. – Т. 116. – №. 12. – С. 18901897.70. Boman K., Olofsson, M., Bergman, Aet al. Anaemia, but not irondeficiency, is associated with clinical symptoms and quality of life inpatients with severe heart failure and palliative home care: A substudy of thePREFER trial // European journal of internal medicine.
– 2017. – Т. 46. – С.35-40.71. Boulogne M. , Sadoune, M., Launay, J. M. et al. Inflammation versusmechanical stretch biomarkers over time in acutely decompensated heartfailure with reduced ejection fraction // International journal of cardiology. –2017. – Т. 226. – С. 53-59.11072. Briasoulis A., Androulakis, E., Christophides, T. et al.
The role ofinflammation and cell death in the pathogenesis, progression and treatmentof heart failure // Heart failure reviews. – 2016. – Т. 21. – №. 2. – С. 169176.73. Burns D. L., Mascioli E. A., Bistrian B. R. Parenteral iron dextran therapy: areview // Nutrition (Burbank, Los Angeles County, Calif.). – 1995. – Т. 11.– №. 2. – С. 163-168.74. Camaschella C. Iron and hepcidin: a story of recycling and balance //ASHEducation Program Book. – 2013. – Т. 2013. – №. 1.
– С. 1-8.75. Camaschella C. Iron-deficiency anemia // New England journal of medicine.– 2015. – Т. 372. – №. 19. – С. 1832-1843.76. Cappellini M. D. , Comin‐Colet,al.Iron deficiencyJ., de Francisco, A. eacross chronic inflammatory conditions: International expert opinion ondefinition, diagnosis and management //American journal of hematology. –2017. С. 1068–1078.77. Caramelo C., Just S., Gil P.
Anemia in heart failure: pathophysiology,pathogenesis, treatment, and incognitae // Revista Española de Cardiología(English Edition). – 2007. – Т. 60. – №. 8. – С. 848-860.78. Carson J. L., Adamson J. W. Iron deficiency and heart disease: ironcladevidence? //ASH Education Program Book. – 2010. – Т. 2010. – №. 1. – С.348-350.79. Cartwright G. E. The anemia of chronic disorders // Seminars inhematology.
– 1966. – Т. 3. – №. 4. – С. 351.80. Castagna A., Campostrini N., Zaninotto F et al. Hepcidin assay in serum bySELDI-TOF-MS and other approaches // Journal of proteomics. – 2010. – Т.73. – №. 3. – С. 527-536.81. Chatterjee B., Nydegger U. E., Mohacsi P. Serum erythropoietin in heartfailure patients treated with ACEjournal of heart failure.
– 2000. – Т. 2. – №. 4. – С. 393-398.‐inhibit11182. Cleland J. G. F., Zhang, J., Pellicori, P.et al. Prevalence and outcomes ofanemia and hematinic deficiencies in patients with chronic heart failure//JAMA cardiology. – 2016. – Т. 1. – №. 5. – С. 539-547.83. Cohen-Solal A., Leclercq, C., Deray, G. et al. Iron deficiency: an emergingtherapeutic target in heart failure // Heart.
– 2014. – Т. 100. – №. 18. – С.1414-1420.84. Cromie N., Lee C., Struthers A. D. Anaemia in chronic heart failure: what isits frequency in the UK and its underlying causes? // Heart. – 2002. – Т. 87.– №. 4. – С. 377-378.85. D’Alessandro R, Masarone D, Buono A, et al. Natriuretic peptides:molecular biology, pathophysiology and clinical implications for thecardiologist // Future Cardiology.- 2013- Т. №.4.- С. 519-534.86.
da Silva Viana P. Á., Aragão, V. T., Vasconcelos, E. C. et al. Anemia as aPredictor of Mortality in Patients with Decompensated Heart Failure //Journal of Pharmacy and Pharmacology. – 2018. – Т. 6. – С. 481-487.87. D'Angelo G. Role of hepcidin in the pathophysiology and diagnosis ofanemia // Blood research.
– 2013. – Т. 48. – №.1. – С.10-15.88. de Bruin AM, Demirel O, Hooibrink B. et al. Interferon-γ impairsproliferation of hematopoietic stem cells in mice // Blood. – 2013. – Т. 121.– №. 18. – С. 3578-3585.89. De Domenico I., Ward D.M., Langelier C. et al. The molecular mechanismof hepcidin-mediated ferroportin down-regulation // Molecular biology ofthe cell. – 2007. – Т.
18. – №. 7. – С. 2569-2578.90. Demirag M. D., Haznedaroglu, S., Sancak, B. et al. Circulating hepcidin inthe crossroads of anemia and inflammation associated with rheumatoidarthritis // Internal medicine. – 2009. – Т. 48. – №. 6. – С. 421-426.91.
Denz H., Orth, B., Huber, P. et al. Immune activation and anemia of chronicdisorders [letter; comment] // Blood. – 1993. – Т. 81. – №. 5. – С. 14041404.11292. Deswal A., Petersen, N. J., Feldman, A. M. et al. Cytokines and cytokinereceptors in advanced heart failure: an analysis of the cytokine databasefrom the Vesnarinone trial (VEST) // Circulation. – 2001.
– Т. 103. – №. 16.– С. 2055-2059.93. Dick S. A., Epelman S. Chronic heart failure and inflammation: what do wereally know? // Circulation research. – 2016. – Т. 119. – №. 1. – С. 159-176.94. Dignass A. U., Gasche, C., Bettenworth, D. et al. European consensus on thediagnosis and management of iron deficiency and anaemia in inflammatorybowel diseases // Journal of Crohn's and Colitis. – 2015. – Т. 9.
– №. 3. – С.211-222.95. Divakaran V, Mehta S, Yao D. et al. Hepcidin in anemia of chronic heartfailure //American journal of hematology. – 2011. – Т. 86. – №. 1. – С. 107109.96. Dodds R. M., Sayer A. A. Sarcopenia, frailty and mortality: the evidence isgrowing // Age Ageing. - 2016.
Т.45. -№5. С.- 570–571.97. Drozd М., Jankowska E.A., Banasiak W. et al. Iron therapy in patients withheart failure and iron deficiency: review of iron preparations forpractitioners //American Journal of Cardiovascular Drugs. – 2017. – Т. 17. –№. 3. – С. 183-201.98. Ebner N, Jankowska EA, Ponikowski P, et al. The impact of iron deficiencyand anaemia on exercise capacity and outcomes in patients with chronicheart failure. Results from the studies investigating co-morbiditiesaggravating heart failure // International journal of cardiology. – 2016.
– Т.205. – С. 6-12.99. Enjuanes C., Klip, I. T., Bruguera, J.et al. Iron deficiency and health-relatedquality of life in chronic heart failure: results from a multicenter Europeanstudy // International journal of cardiology. – 2014. – Т. 174. – №. 2. – С.268-275.113100.Evans P, Cindrova-Davies T, Muttukrishna S et al. Evans P. Hepcidinand iron species distribution inside the first-trimester human gestational sac// Molecular human reproduction. – 2010. – Т. 17.
– №. 4. – С. 227-232.101.Ezekowitz J. A., McAlister F. A., Armstrong P. W. Anemia iscommon in heart failure and is associated with poor outcomes: insights froma cohort of 12 065 patients with new-onset heart failure // Circulation. –2003. – Т. 107. – №. 2. – С. 223-225.102.Felker G. M., Shaw, L. K., Stough, W. G.et al. Anemia in patientswith heart failure and preserved systolic function //American heart journal. –2006.
– Т. 151. – №. 2. – С. 457-462.103.Finberg K. E. Regulation of systemic iron homeostasis // Currentopinion in hematology. – 2013. – Т. 20. – №. 3. – С. 208-214.104.Fleming R. E., Sly W. S. Hepcidin: a putative iron-regulatoryhormone relevant to hereditary hemochromatosis and the anemia of chronicdisease // Proceedings of the National Academy of Sciences. – 2001. – Т.98. – №. 15. – С. 8160-8162.105.Fontes J.
A., Rose N. R., Čiháková D. The varying faces of IL-6:From cardiac protection to cardiac failure // Cytokine. – 2015. – Т. 74. – №.1. – С. 62-68.106.Fried L. P., Tangen C. M., Walston J. Et al. Frailty in older adults:evidence for a phenotype // The Journals of Gerontology Series A:Biological Sciences and Medical Sciences. – 2001. – Т. 56. – №. 3. – С.146-157.107.Ganz T.
Hepcidin, a key regulator of iron metabolism and mediator ofanemia of inflammation // Blood. – 2003. – Т. 102. – №. 3. – С. 783-788.108.Ganz T., Nemeth E. Hepcidin and iron homeostasis // Biochimica etBiophysica Acta (BBA)-Molecular Cell Research. – 2012. – Т. 1823. – №.9. – С. 1434-1443.109.Ganz T., Olbina G., Girelli D. et al.
Immunoassay for human serumhepcidin // Blood. – 2008. – Т. 112. – №. 10. – С. 4292-4297.114110.George J. Patal, S., Wexler, D. et al. Circulating erythropoietin levelsand prognosis in patients with congestive heart failure: comparison withneurohormonal and inflammatory markers //Archives of internal medicine.
–2005. – Т. 165. – №. 11. – С. 1304-1309.111.Ghali J. K., Anand, I. S., Abraham, W. T. et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure andanemia // Circulation. – 2008. – Т. 117. – №. 4. – С. 526-535.112.Glezeva N., Voon, V., Watson, C. et al. Exaggerated inflammationand monocytosis associate with diastolic dysfunction in heart failure withpreserved ejection fraction: evidence of M2 macrophage activation indisease pathogenesis // Journal of cardiac failure. – 2015. – Т.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
